Table 1 Difference in baseline characteristics between group A and group B
Baseline characteristics | In total Absolute value (%) | Group A (PCR + ; CT ±) Absolute value (%) | Group B (PCR-; CT +) Absolute value (%) |
|---|---|---|---|
Number of patients | 153 (100) | 107 (70) | 46 (30) |
Age (median) | 68 | 67 | 69 |
Sex (male/female) | 95/58 | 70/37 | 25/21 |
Comorbidities (Comorbidity Score index points*) | |||
Coronary artery diseasea (1 point) | 17 (11) | 15 (14) | 2 (4) |
Heart diseaseb (1 point) | 41 (27) | 27 (25) | 14 (30) |
Cerebrovascular diseasec (1 point) | 11 (7) | 6 (5) | 5 (11) |
Dementia/Parkinson disease (1 point) | 17 (11) | 8 (8) | 9 (20) |
Gastric ulcer disease (1 point) | 5 (3) | 4 (4) | 1 (2) |
Chronic pulmonary disease (1 point) | 17 (11) | 12 (11) | 5 (11) |
Peripheral vascular disease (1 point) | 9 (6) | 7 (7) | 2 (4) |
Mild liver diseased (1 point) | 1 (1) | 1 (1) | 0 (0) |
Liver cirrhosis (3 point) | 4 (3) | 3 (3) | 1 (2) |
Diabetes without end organ failure (1 point) | 22 (14) | 18 (17) | 4 (9) |
Diabetes with end organ failure (2 points) | 8 (5) | 7 (7) | 1 (2) |
Renal insufficiency (2 points) | 14 (9) | 11 (10) | 3 (7) |
Active tumor diseasee (2 points) | 11 (7) | 9 (8) | 2 (4) |
Metastatic tumor disease (6 points) | 16 (10) | 8 (8) | 8 (17) |
AIDS (6 points) | - | - | - |
Comorbidity Score points in total (median/mean) | 314 (1/2.05) | 209 (1/1.95) | 105 (1/2.28) |
Median duration of hospitalization in days | 16 | 16 | 13.5 |
Number of patients with typical CT findings compatible with a high level of certainty for COVID-19 | 125 (82) | 85 (79) | 30 (65) |
Deaths | 25 (16) | 18 (17) | 7 (15) |
ICU admission | 53 (35) | 41 (38) | 12 (26) |
Treatment (Remdesivir) | 17 | 17 | 0 |